Pilot Study of Intranasal Oxytocin Effects in Adults With Arginine-Vasopressin Deficiency

What this Trial Is About

Researchers are evaluating the effects of single-dose intranasal oxytocin compared to placebo in adults with arginine-vasopressin deficiency. This randomized, double-blind, placebo-controlled crossover pilot study aims to assess how oxytocin influences anxiety, depression, and social-emotional functioning. The study includes adult men and women aged 18 years and above. Participants undergo three main study visits during Part A, where they receive either 6 IU or 24 IU doses of oxytocin or placebo in a randomized order. After completing Part A, participants may opt to join Part B, a two-week substudy involving repeated doses of 6 IU oxytocin or placebo administered three times daily. Both parts use a crossover and placebo-controlled design to compare outcomes. Throughout the study, participants complete assessments of emotional behavior at specified times after dosing, including tasks measuring anxious behavior, depressive behavior, and socioemotional functioning. Researchers monitor responses using tasks such as the dot-probe, probabilistic reward, and emotion recognition tests. The study involves screening for eligibility, followed by multiple visits for dosing and evaluations, with the entire study expected to complete by June 2027.

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency